Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Protagonist Therapeutics, Inc. (PTGX)
USD130.40
+0.51 (+0.39%)
US NASDAQ Healthcare Biotechnology
Address
7707 Gateway Boulevard 94560-1160
Newark, CA, US
Newark, CA, US
CEO
Dinesh V. Patel
Website
protagonist-inc.com
IPO
2016-08-11
CIK 1377121 ISIN US74366E1029
Description
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
News Sentiment (7d)
3 articles
- PTGX Stock Surges 64% in Six Months: What Is Driving the Rally? Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD130.40
+0.51 (+0.39%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
698.4K
Beta
1.83
Float Shares
51.94M
Free Float %
81.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.43% | -3.48% | +1.14% | +21.99% | +17.80% | +14.44% | +120.79% | +293.97% | +241.24% | +754.27% | +754.27% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (26 ratings, all time)
Buy
Price Targets & DCF
Current price
130.40
Low
108.00
-17.2%
Consensus
115.40
-11.5%
Median
117.00
-10.3%
High
121.00
-7.2%
Ratings Trend (MoM)
92% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 8 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
115.50
-11.4%
|
| Last Quarter | 3 |
117.33
-10.0%
|
| Last Year | 10 |
103.30
-20.8%
|
| All Time | 17 |
86.00
-34.0%
|
Quality scores
Altman Z-Score
93.90
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-89.4% Q1'26: +99.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-148.5% Q1'26: +128.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+34.9% Q1'26: -87.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-281.0% Q1'26: -6.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-224.2% Q1'26: -12.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-2.3% ★ Q1'26: +12.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.08× Q1'26: -0.75× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 6 EPS Ana. |
Dec 2027 8 Rev. Ana. 8 EPS Ana. |
Dec 2028 8 Rev. Ana. 4 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
20.06M
est: 17.66M (+13.6%)
|
30.93M
est: 33.60M (-8.0%)
|
231.0K
est: 1.74M (-86.7%)
|
28.63M
est: 25.69M (+11.4%)
|
27.36M
est: 23.20M (+17.9%)
|
26.58M
est: 29.85M (-11.0%)
|
60.00M
est: 314.95M (-80.9%)
|
434.43M
est: 382.04M (+13.7%)
|
46.02M
est: 47.04M (-2.2%)
|
489.11M
458.80M – 529.90M
+939.8% YoY
|
156.34M
100.29M – 233.03M
-68.0% YoY
|
311.39M
262.88M – 401.86M
+99.2% YoY
|
430.07M
363.06M – 555.02M
+38.1% YoY
|
624.99M
527.62M – 806.57M
+45.3% YoY
|
| EBITDA |
-36.55M
est: -12.07M (-202.9%)
|
-39.20M
est: -22.96M (-70.7%)
|
-77.01M
est: -1.19M (-6,396.3%)
|
-63.57M
est: -17.55M (-262.2%)
|
-123.07M
est: -119.58M (-2.9%)
|
-128.00M
est: -134.02M (+4.5%)
|
-90.34M
est: -215.18M (+58.0%)
|
253.67M
est: -261.02M (+197.2%)
|
-128.09M
est: -32.14M (-298.5%)
|
-334.17M
-362.04M – -313.46M
-939.8% YoY
|
-106.82M
-159.21M – -68.52M
+68.0% YoY
|
-212.75M
-274.56M – -179.60M
-99.2% YoY
|
-293.83M
-379.20M – -248.05M
-38.1% YoY
|
-427.00M
-551.07M – -360.48M
-45.3% YoY
|
| EBIT |
-36.96M
est: -12.07M (-206.1%)
|
-39.72M
est: -22.97M (-72.9%)
|
-77.71M
est: -1.19M (-6,452.0%)
|
-64.52M
est: -17.56M (-267.4%)
|
-125.85M
est: -122.58M (-2.7%)
|
-131.37M
est: -138.62M (+5.2%)
|
-93.65M
est: -215.30M (+56.5%)
|
252.84M
est: -261.16M (+196.8%)
|
-129.31M
est: -32.16M (-302.1%)
|
-334.35M
-362.24M – -313.64M
-939.8% YoY
|
-106.87M
-159.30M – -68.56M
+68.0% YoY
|
-212.87M
-274.71M – -179.70M
-99.2% YoY
|
-293.99M
-379.41M – -248.19M
-38.1% YoY
|
-427.24M
-551.37M – -360.68M
-45.3% YoY
|
| Net Income |
-36.96M
est: -148.12M (+75.0%)
|
-38.92M
est: -108.42M (+64.1%)
|
-77.19M
est: -191.85M (+59.8%)
|
-66.15M
est: -125.99M (+47.5%)
|
-125.55M
est: -122.29M (-2.7%)
|
-127.39M
est: -137.72M (+7.5%)
|
-78.96M
est: 162.11M (-148.7%)
|
275.19M
est: 229.60M (+19.9%)
|
-130.15M
est: -114.71M (-13.5%)
|
312.72M
-124.03M – 507.69M
+372.6% YoY
|
-65.80M
-74.95M – -8.11M
-121.0% YoY
|
3.95M
-2.15B – 3.00B
+106.0% YoY
|
168.47M
134.35M – 232.10M
+4,169.6% YoY
|
312.78M
249.43M – 430.92M
+85.7% YoY
|
| SGA |
11.78M
est: 12.35M (-4.6%)
|
13.70M
est: 23.50M (-41.7%)
|
15.75M
est: 1.21M (+1,197.7%)
|
18.64M
est: 17.97M (+3.7%)
|
27.20M
est: 16.23M (+67.6%)
|
31.74M
est: 20.88M (+52.0%)
|
33.49M
est: 240.69M (-86.1%)
|
43.46M
est: 291.97M (-85.1%)
|
44.85M
est: 35.95M (+24.8%)
|
373.79M
350.63M – 404.96M
+939.8% YoY
|
119.48M
76.64M – 178.08M
-68.0% YoY
|
237.97M
200.90M – 307.11M
+99.2% YoY
|
328.67M
277.46M – 424.16M
+38.1% YoY
|
477.63M
403.22M – 616.40M
+45.3% YoY
|
| EPS |
-2.09
est: -2.28 (+8.2%)
|
-1.74
est: -1.67 (-4.4%)
|
-2.98
est: -2.95 (-1.1%)
|
-1.92
est: -1.94 (+0.8%)
|
-2.65
est: -2.71 (+2.3%)
|
-2.52
est: -2.57 (+2.0%)
|
-1.39
est: 2.73 (-150.9%)
|
4.47
est: 3.45 (+29.5%)
|
-2.05
est: -1.96 (-4.3%)
|
3.84
-1.95 – 7.99
+295.2% YoY
|
-0.76
-1.18 – -0.13
-119.7% YoY
|
1.63
-33.87 – 47.23
+315.6% YoY
|
2.65
2.11 – 3.65
+62.7% YoY
|
4.92
3.92 – 6.78
+85.7% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-06 | Wedbush | Outperform | Outperform | Maintain |
| 2026-04-15 | Truist Securities | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-132.15M
OE per share TTM
-2.00
Owner's Yield
-2.03%
Maintenance CapEx ratio
68.07%
Maint CapEx / Avg PPE
8.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
71
Total invested
130.11M
Insider transactions (90d)
2
Beneficial owners (>5%)
28
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Constellation Brands, Inc. | 5.56M | 46.00% | — | 6.69M | — | 6.78M | CO | BOSTON, MASSACHUSETTS | 2022-07-11 | ↗ |
| 2 | Michael B. Fisch | 3.93M | 9.00% | — | 3.93M | — | — | IN | United States | 2021-02-16 | ↗ |
| 3 | Philip D. Dreyfuss | 3.93M | 9.00% | — | 3.93M | — | — | IN | United States | 2021-02-16 | ↗ |
| 4 | Rajiv A. Patel | 3.93M | 9.00% | — | 3.93M | — | — | IN | United States | 2021-02-16 | ↗ |
| 5 | Richard B. Fried | 3.93M | 9.00% | — | 3.93M | — | — | IN | United States | 2021-02-16 | ↗ |
| 6 | (1) BlackRock, Inc. | 3.28M | 6.90% | 3.24M | — | 3.28M | — | HC | Delaware | 2022-02-03 | ↗ |
| 7 | Point72 Asset Management, L.P. | 3.19M | 5.50% | — | 3.19M | — | — | PN | United States | 2023-12-18 | ↗ |
| 8 | Point72 Capital Advisors, Inc. | 3.19M | 5.50% | — | 3.19M | — | — | CO | United States | 2023-12-18 | ↗ |
| 9 | Steven A. Cohen | 3.19M | 5.50% | — | 3.19M | — | — | IN | United States | 2023-12-18 | ↗ |
| 10 | STATE STREET CORPORATION | 3.18M | 5.40% | — | 3.03M | — | — | HC | MA | 2024-10-16 | ↗ |
| 11 | The Vanguard Group - 23-1945930 | 3.10M | 6.30% | — | — | — | 74.4K | IA | Pennsylvania For | 2023-02-09 | ↗ |
| 12 | Adage Capital Advisors, L.L.C. | 2.96M | 5.44% | — | 2.96M | — | — | OO | Delaware | 2023-04-13 | ↗ |
| 13 | Adage Capital Partners GP, L.L.C. | 2.96M | 5.44% | — | 2.96M | — | — | OO | Delaware | 2023-04-13 | ↗ |
| 14 | Adage Capital Partners, L.P. | 2.96M | 5.44% | — | 2.96M | — | — | PN | Delaware | 2023-04-13 | ↗ |
| 15 | Phillip Gross | 2.96M | 5.44% | — | 2.96M | — | — | IN | United States | 2023-04-13 | ↗ |
| 16 | Robert Atchinson | 2.96M | 5.44% | — | 2.96M | — | — | IN | United States | 2023-04-13 | ↗ |
| 17 | Biotechnology Value Fund, L.P. | 2.63M | 5.10% | — | 2.63M | — | 2.63M | PN | Delaware | 2023-03-20 | ↗ |
| 18 | Farallon Capital Offshore Investors II, L.P. | 1.86M | 4.30% | — | 1.86M | — | — | PN | Cayman Islands | 2021-02-16 | ↗ |
| 19 | Farallon Capital Institutional Partners, L.P. | 834.3K | 2.00% | — | 834.3K | — | — | PN | California | 2021-02-16 | ↗ |
| 20 | Consonance Capital Opportunity Fund Management LP | 268.4K | 0.63% | — | 268.4K | — | — | IA, PN | USA | 2021-02-17 | ↗ |
| 21 | Four Crossings Institutional Partners V, L.P. | 128.7K | 0.30% | — | 128.7K | — | — | PN | Delaware | 2021-02-16 | ↗ |
| 22 | Farallon Capital Institutional Partners III, L.P. | 92.7K | 0.20% | — | 92.7K | — | — | PN | Delaware | 2021-02-16 | ↗ |
| 23 | Cubist Systematic Strategies, LLC | 546.00 | 4.00% | — | 546.00 | — | 546.00 | OO | Delaware | 2022-02-14 | ↗ |
| 24 | 2. | 10.00 | 3.60% | — | 1.78M | — | — | IA, HC, OO | Delaware | 2023-01-03 | ↗ |
| 25 | Point72 Hong Kong Limited | — | 4.00% | — | — | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 26 | Consonance Capital Management LP | — | 0.00% | — | — | — | — | IA, PN | Delaware USA | 2022-02-14 | ↗ |
| 27 | Consonance Capman GP LLC | — | 0.00% | — | — | — | — | HC, OO | Delaware USA | 2022-02-14 | ↗ |
| 28 | Mitchell Blutt | — | 0.00% | — | — | — | — | HC, IN | Delaware USA | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
71
-258 vs prev Q
New positions
13
Closed positions
259
Increased
32
Reduced
24
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 229.6K +229.6K (+100.0%) | 20.05B +20.1B (+100.0%) | 0.36% +0.360 pp | 11.76% +11.763 pp | USD87.34 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 9.72M +311.8K (+3.3%) | 848.60M +223.9M (+35.8%) | 15.24% +0.428 pp | 0.01% +0.003 pp | USD46.36 +88.4% | 6 qtrs — |
| 3 | FARALLON CAPITAL MANAGEMENT LLC | 6.14M -52.0K (-0.8%) | 536.62M +125.0M (+30.4%) | 9.63% -0.122 pp | 2.53% +0.847 pp | USD19.79 +341.3% | 33 qtrs — |
| 4 | VANGUARD GROUP INC | 5.41M +1.2M (+27.2%) | 472.83M +190.0M (+67.2%) | 8.49% +1.786 pp | 0.01% +0.003 pp | USD38.07 +129.4% | 38 qtrs — |
| 5 | RTW INVESTMENTS, LP | 5.06M -697.2K (-12.1%) | 441.86M +59.5M (+15.6%) | 7.93% -1.130 pp | 4.43% -0.286 pp | USD24.30 +259.4% | 26 qtrs — |
| 6 | STATE STREET CORP | 3.20M +33.9K (+1.1%) | 279.46M +69.2M (+32.9%) | 5.02% +0.033 pp | 0.01% +0.002 pp | USD33.92 +157.5% | 38 qtrs — |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 3.17M +1.3M (+66.2%) | 276.99M +150.2M (+118.5%) | 4.97% +1.968 pp | 0.05% +0.026 pp | USD66.12 +32.1% | 6 qtrs — |
| 8 | UBS GROUP AG | 2.77M +874.0K (+46.1%) | 241.93M +116.0M (+92.1%) | 4.34% +1.358 pp | 0.04% +0.020 pp | USD64.03 +36.4% | 38 qtrs — |
| 9 | JANUS HENDERSON GROUP PLC | 2.65M +1.5M (+140.7%) | 231.35M +158.2M (+216.2%) | 4.16% +2.422 pp | 0.10% +0.070 pp | USD76.52 +14.1% | 12 qtrs — |
| 10 | JOHNSON & JOHNSON | 2.45M +— (+0.0%) | 213.91M +51.2M (+31.5%) | 3.84% -0.016 pp | 38.54% +6.420 pp | USD17.72 +392.9% | 18 qtrs — |
| 11 | INVESCO LTD. | 1.57M +564.1K (+56.2%) | 136.94M +70.3M (+105.4%) | 2.46% +0.878 pp | 0.02% +0.011 pp | USD63.37 +37.8% | 28 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 1.45M +36.3K (+2.6%) | 126.92M +32.8M (+34.8%) | 2.28% +0.048 pp | 0.01% +0.002 pp | USD25.73 +239.4% | 38 qtrs — |
| 13 | WOODLINE PARTNERS LP | 1.41M -29.5K (-2.0%) | 123.04M +27.5M (+28.8%) | 2.21% -0.056 pp | 0.48% +0.027 pp | USD47.98 +82.0% | 8 qtrs — |
| 14 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.40M +180.3K (+14.8%) | 122.34M +41.3M (+50.9%) | 2.20% +0.275 pp | 0.01% +0.005 pp | USD44.95 +94.3% | 12 qtrs — |
| 15 | PERCEPTIVE ADVISORS LLC | 1.35M +320.3K (+31.1%) | 117.95M +49.5M (+72.4%) | 2.12% +0.496 pp | 2.10% +0.126 pp | USD43.54 +100.6% | 12 qtrs — |
| 16 | CITADEL ADVISORS LLC | 1.13M +888.8K (+373.6%) | 98.40M +82.6M (+522.7%) | 1.77% +1.392 pp | 0.01% +0.012 pp | USD82.26 +6.2% | 21 qtrs — |
| 17 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1.10M -40.7K (-3.6%) | 96.00M +20.3M (+26.8%) | 1.72% -0.071 pp | 0.65% +0.110 pp | USD53.05 +64.6% | 9 qtrs — |
| 18 | ADAR1 CAPITAL MANAGEMENT, LLC | 1.05M +60.0K (+6.1%) | 91.63M +25.9M (+39.4%) | 1.65% +0.088 pp | 6.73% +0.557 pp | USD36.19 +141.3% | 9 qtrs — |
| 19 | MARSHALL WACE, LLP | 1.02M -60.6K (-5.6%) | 89.52M +17.4M (+24.1%) | 1.61% -0.102 pp | 0.08% +0.008 pp | USD66.43 +31.5% | 2 qtrs — |
| 20 | GOLDMAN SACHS GROUP INC | 961.1K +179.4K (+23.0%) | 83.95M +32.0M (+61.7%) | 1.51% +0.276 pp | 0.01% +0.004 pp | USD44.78 +95.0% | 33 qtrs — |
| 21 | MORGAN STANLEY | 879.0K +110.7K (+14.4%) | 76.77M +25.7M (+50.4%) | 1.38% +0.169 pp | 0.00% +0.002 pp | USD48.26 +81.0% | 38 qtrs — |
| 22 | BANK OF AMERICA CORP /DE/ | 867.6K +37.7K (+4.5%) | 75.77M +20.6M (+37.5%) | 1.36% +0.054 pp | 0.01% +0.002 pp | USD51.33 +70.2% | 37 qtrs — |
| 23 | NORTHERN TRUST CORP | 575.1K -28.1K (-4.7%) | 50.23M +10.2M (+25.4%) | 0.90% -0.048 pp | 0.01% +0.001 pp | USD24.16 +261.5% | 38 qtrs — |
| 24 | NATIONALE-NEDERLANDEN POWSZECHNE TOWARZYSTWO EMERYTALNE S.A. | 571.8K +571.8K (+100.0%) | 49.94M +49.9M (+100.0%) | 0.90% +0.897 pp | 4.43% +4.432 pp | USD87.34 +0.0% | 1 qtrs NEW |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 556.8K +3.9K (+0.7%) | 48.63M +11.9M (+32.4%) | 0.87% +0.003 pp | 0.01% +0.002 pp | USD25.99 +236.1% | 27 qtrs — |
| 26 | FMR LLC | 539.9K +19.2K (+3.7%) | 47.15M +12.6M (+36.3%) | 0.85% +0.027 pp | 0.00% +0.001 pp | USD34.17 +155.6% | 38 qtrs — |
| 27 | AMERICAN CENTURY COMPANIES INC | 535.4K -64.6K (-10.8%) | 46.76M +6.9M (+17.3%) | 0.84% -0.105 pp | 0.02% +0.003 pp | USD44.12 +98.0% | 13 qtrs — |
| 28 | PICTET ASSET MANAGEMENT HOLDING SA | 529.6K -292.6K (-35.6%) | 46.26M -8.4M (-15.3%) | 0.83% -0.464 pp | 0.04% -0.008 pp | USD50.22 +73.9% | 7 qtrs — |
| 29 | CLEARBRIDGE INVESTMENTS, LLC | 489.8K +489.8K (+100.0%) | 42.78M +42.8M (+100.0%) | 0.77% +0.768 pp | 0.03% +0.034 pp | USD87.34 +0.0% | 1 qtrs NEW |
| 30 | COMMODORE CAPITAL LP | 450.0K -575.0K (-56.1%) | 39.30M -28.8M (-42.3%) | 0.71% -0.908 pp | 2.62% -0.708 pp | USD55.27 +58.0% | 3 qtrs — |
| 31 | DIMENSIONAL FUND ADVISORS LP | 414.4K -24.1K (-5.5%) | 36.19M +7.1M (+24.3%) | 0.65% -0.041 pp | 0.01% +0.001 pp | USD50.94 +71.5% | 31 qtrs — |
| 32 | 683 CAPITAL MANAGEMENT, LLC | 380.7K -26.8K (-6.6%) | 33.25M +6.2M (+22.8%) | 0.60% -0.045 pp | 1.45% +0.032 pp | USD25.14 +247.4% | 13 qtrs — |
| 33 | VOYA INVESTMENT MANAGEMENT LLC | 366.2K +60.7K (+19.9%) | 31.98M +11.7M (+57.6%) | 0.57% +0.093 pp | 0.03% +0.011 pp | USD57.08 +53.0% | 22 qtrs — |
| 34 | BANK OF NEW YORK MELLON CORP | 350.4K -12.9K (-3.5%) | 30.60M +6.5M (+26.8%) | 0.55% -0.023 pp | 0.01% +0.001 pp | USD32.61 +167.8% | 38 qtrs — |
| 35 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 348.6K +280.1K (+408.9%) | 30.45M +25.9M (+569.1%) | 0.55% +0.439 pp | 0.00% +0.003 pp | USD79.01 +10.5% | 21 qtrs — |
| 36 | PRINCIPAL FINANCIAL GROUP INC | 347.9K +21.8K (+6.7%) | 30.39M +8.7M (+40.3%) | 0.55% +0.032 pp | 0.02% +0.005 pp | USD46.54 +87.7% | 14 qtrs — |
| 37 | JENNISON ASSOCIATES LLC | 331.2K +331.2K (+100.0%) | 28.92M +28.9M (+100.0%) | 0.52% +0.519 pp | 0.02% +0.017 pp | USD87.34 +0.0% | 1 qtrs NEW |
| 38 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 330.8K -121.0K (-26.8%) | 28.89M -1.1M (-3.7%) | 0.52% -0.193 pp | 0.03% -0.045 pp | USD48.67 +79.5% | 6 qtrs — |
| 39 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 232.8K -485.4K (-67.6%) | 20.34M -27.4M (-57.4%) | 0.37% -0.766 pp | 0.03% -0.045 pp | USD53.10 +64.5% | 23 qtrs — |
| 40 | KENNEDY CAPITAL MANAGEMENT LLC | 221.4K +13.0K (+6.2%) | 19.34M +5.5M (+39.7%) | 0.35% +0.019 pp | 0.41% +0.104 pp | USD39.60 +120.6% | 20 qtrs — |
| 41 | HOLOCENE ADVISORS, LP | 210.0K +210.0K (+100.0%) | 18.34M +18.3M (+100.0%) | 0.33% +0.329 pp | 0.04% +0.039 pp | USD87.34 +0.0% | 3 qtrs — |
| 42 | SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) | 205.6K +126.8K (+160.9%) | 17.95M +12.7M (+243.0%) | 0.32% +0.198 pp | 0.07% +0.051 pp | USD70.07 +24.6% | 11 qtrs — |
| 43 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 203.4K -24.7K (-10.8%) | 17.77M +2.6M (+17.2%) | 0.32% -0.040 pp | 0.06% +0.004 pp | USD47.52 +83.8% | 6 qtrs — |
| 44 | ALYESKA INVESTMENT GROUP, L.P. | 199.5K +199.5K (+100.0%) | 17.43M +17.4M (+100.0%) | 0.31% +0.313 pp | 0.05% +0.049 pp | USD87.34 +0.0% | 1 qtrs NEW |
| 45 | BIOIMPACT CAPITAL LLC | 199.5K +199.5K (+100.0%) | 17.42M +17.4M (+100.0%) | 0.31% +0.313 pp | 1.99% +1.993 pp | USD87.34 +0.0% | 1 qtrs NEW |
| 46 | BARCLAYS PLC | 187.6K +60.6K (+47.8%) | 16.39M +10.7M (+186.8%) | 0.29% +0.094 pp | 0.00% +0.003 pp | USD58.98 +48.1% | 37 qtrs — |
| 47 | RAYMOND JAMES FINANCIAL INC | 181.5K -112.8K (-38.3%) | 15.84M -3.7M (-19.0%) | 0.28% -0.179 pp | 0.00% -0.001 pp | USD39.30 +122.2% | 5 qtrs — |
| 48 | NAN FUNG TRINITY (HK) LTD | 180.7K +35.8K (+24.7%) | 15.78M +6.2M (+63.9%) | 0.28% +0.055 pp | 1.25% +0.290 pp | USD62.23 +40.4% | 3 qtrs — |
| 49 | CAPTION MANAGEMENT, LLC | 174.8K +156.8K (+871.1%) | 15.27M +14.1M (+1,176.8%) | 0.27% +0.246 pp | 0.10% +0.095 pp | USD83.33 +4.8% | 4 qtrs — |
| 50 | AFFINITY ASSET ADVISORS, LLC | 172.1K -48.5K (-22.0%) | 15.03M +378.9K (+2.6%) | 0.27% -0.077 pp | 0.86% -0.420 pp | USD46.10 +89.5% | 5 qtrs — |
| 51 | BOXER CAPITAL MANAGEMENT, LLC | 170.0K +60.0K (+54.5%) | 14.85M +7.5M (+103.2%) | 0.27% +0.093 pp | 3.25% +0.921 pp | USD69.87 +25.0% | 3 qtrs — |
| 52 | AMERIPRISE FINANCIAL INC | 169.5K +16.3K (+10.7%) | 14.81M +4.6M (+45.5%) | 0.27% +0.025 pp | 0.00% +0.001 pp | USD50.82 +71.9% | 6 qtrs — |
| 53 | DUQUESNE FAMILY OFFICE LLC | 159.7K +— (+0.0%) | 13.95M +3.3M (+31.5%) | 0.25% -0.001 pp | 0.31% +0.049 pp | USD66.43 +31.5% | 2 qtrs — |
| 54 | TD ASSET MANAGEMENT INC | 158.7K +8.3K (+5.5%) | 13.86M +3.9M (+38.7%) | 0.25% +0.012 pp | 0.01% +0.003 pp | USD39.12 +123.3% | 12 qtrs — |
| 55 | JPMORGAN CHASE & CO | 155.3K -97.1K (-38.5%) | 13.56M -3.2M (-19.1%) | 0.24% -0.154 pp | 0.00% 0.000 pp | USD32.13 +171.8% | 38 qtrs — |
| 56 | RHUMBLINE ADVISERS | 155.0K -9.0K (-5.5%) | 13.53M +2.6M (+24.2%) | 0.24% -0.015 pp | 0.01% +0.002 pp | USD32.35 +170.0% | 27 qtrs — |
| 57 | QUBE RESEARCH & TECHNOLOGIES LTD | 153.9K +153.9K (+100.0%) | 13.44M +13.4M (+100.0%) | 0.24% +0.241 pp | 0.01% +0.014 pp | USD87.34 +0.0% | 10 qtrs — |
| 58 | LEGAL & GENERAL GROUP PLC | 149.2K -6.7K (-4.3%) | 13.03M +2.7M (+25.9%) | 0.23% -0.012 pp | 0.00% +0.001 pp | USD40.07 +118.0% | 27 qtrs — |
| 59 | SEGALL BRYANT & HAMILL, LLC | 129.1K +5.9K (+4.8%) | 11.27M +3.1M (+37.8%) | 0.20% +0.009 pp | 0.15% +0.044 pp | USD57.00 +53.2% | 3 qtrs — |
| 60 | NUVEEN, LLC | 125.9K -2.5K (-2.0%) | 10.99M +2.5M (+28.9%) | 0.20% -0.005 pp | 0.00% +0.001 pp | USD48.36 +80.6% | 4 qtrs — |
| 61 | PANAGORA ASSET MANAGEMENT INC | 125.4K -23.3K (-15.7%) | 10.95M +1.1M (+10.8%) | 0.20% -0.038 pp | 0.04% -0.001 pp | USD48.36 +80.6% | 4 qtrs — |
| 62 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 114.0K +23.7K (+26.3%) | 9.96M +4.0M (+66.0%) | 0.18% +0.037 pp | 0.02% +0.006 pp | USD66.56 +31.2% | 4 qtrs — |
| 63 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 113.3K -21.8K (-16.1%) | 9.89M +917.9K (+10.2%) | 0.18% -0.035 pp | 0.01% +0.001 pp | USD39.26 +122.5% | 27 qtrs — |
| 64 | PRUDENTIAL FINANCIAL INC | 110.4K -16.0K (-12.7%) | 9.64M +1.2M (+14.8%) | 0.17% -0.026 pp | 0.01% +0.002 pp | USD54.85 +59.2% | 6 qtrs — |
| 65 | HUDSON BAY CAPITAL MANAGEMENT LP | 109.6K +109.6K (+100.0%) | 9.57M +9.6M (+100.0%) | 0.17% +0.172 pp | 0.03% +0.032 pp | USD87.34 +0.0% | 1 qtrs NEW |
| 66 | DEUTSCHE BANK AG\ | 105.5K -11.8K (-10.0%) | 9.21M +1.4M (+18.3%) | 0.17% -0.019 pp | 0.00% +0.000 pp | USD39.49 +121.2% | 38 qtrs — |
| 67 | OPALEYE MANAGEMENT INC. | 105.0K +— (+0.0%) | 9.17M +2.2M (+31.5%) | 0.16% -0.001 pp | 1.21% +0.224 pp | USD22.93 +280.9% | 9 qtrs — |
| 68 | UBS ASSET MANAGEMENT AMERICAS INC | 104.5K -5.7K (-5.2%) | 9.13M +1.8M (+24.7%) | 0.16% -0.010 pp | 0.00% +0.000 pp | USD29.01 +201.1% | 21 qtrs — |
| 69 | SOROS FUND MANAGEMENT LLC | 100.0K +100.0K (+100.0%) | 8.73M +8.7M (+100.0%) | 0.16% +0.157 pp | 0.10% +0.101 pp | USD87.34 +0.0% | 1 qtrs NEW |
| 70 | NEUBERGER BERMAN GROUP LLC | 98.5K -24.9K (-20.2%) | 8.60M +404.7K (+4.9%) | 0.15% -0.040 pp | 0.01% +0.000 pp | USD57.97 +50.7% | 3 qtrs — |
| 71 | SWISS NATIONAL BANK | 98.2K +2.1K (+2.2%) | 8.58M +2.2M (+34.3%) | 0.15% +0.003 pp | 0.01% +0.001 pp | USD27.39 +218.9% | 21 qtrs — |
| 72 | BNP PARIBAS ARBITRAGE, SNC | 97.8K +84.6K (+644.2%) | 8.54M +7.7M (+878.4%) | 0.15% +0.133 pp | 0.00% +0.003 pp | USD82.07 +6.4% | 38 qtrs — |
| 73 | CITIGROUP INC | 94.9K -57.7K (-37.8%) | 8.29M -1.8M (-18.2%) | 0.15% -0.091 pp | 0.00% -0.001 pp | USD52.31 +67.0% | 28 qtrs — |
| 74 | AXIOM INVESTORS LLC /DE | 89.5K +9.4K (+11.7%) | 7.81M +2.5M (+46.8%) | 0.14% +0.014 pp | 0.07% +0.029 pp | USD59.14 +47.7% | 4 qtrs — |
| 75 | ATIKA CAPITAL MANAGEMENT LLC | 86.0K +3.0K (+3.6%) | 7.51M +2.0M (+36.2%) | 0.13% +0.004 pp | 0.79% +0.347 pp | USD67.16 +30.0% | 2 qtrs — |
| 76 | MOODY ALDRICH PARTNERS LLC | 80.6K -62.4K (-43.6%) | 7.04M -2.5M (-25.9%) | 0.13% -0.099 pp | 1.31% -0.489 pp | USD40.49 +115.7% | 11 qtrs — |
| 77 | VICTORY CAPITAL MANAGEMENT INC | 80.6K -4.9K (-5.8%) | 7.04M +1.4M (+23.9%) | 0.13% -0.008 pp | 0.00% +0.001 pp | USD41.58 +110.1% | 8 qtrs — |
| 78 | EAM INVESTORS, LLC | 78.5K -1.6K (-2.0%) | 6.86M +1.6M (+31.0%) | 0.12% -0.003 pp | 0.76% +0.164 pp | USD50.43 +73.2% | 4 qtrs — |
| 79 | FRANKLIN RESOURCES INC | 76.4K -6.5K (-7.8%) | 6.68M +1.2M (+21.2%) | 0.12% -0.011 pp | 0.00% +0.000 pp | USD38.89 +124.6% | 13 qtrs — |
| 80 | GREAT LAKES ADVISORS, LLC | 74.0K -15.2K (-17.1%) | 6.46M +536.6K (+9.1%) | 0.12% -0.024 pp | 0.05% +0.003 pp | USD38.18 +128.8% | 12 qtrs — |
| 81 | HIGHVISTA STRATEGIES LLC | 73.5K -48.1K (-39.6%) | 6.42M -1.7M (-20.5%) | 0.12% -0.076 pp | 1.65% -0.327 pp | USD54.58 +60.0% | 11 qtrs — |
| 82 | ALLIANCEBERNSTEIN L.P. | 73.2K -187.6K (-71.9%) | 6.40M -10.9M (-63.1%) | 0.11% -0.296 pp | 0.00% -0.003 pp | USD55.31 +57.9% | 26 qtrs — |
| 83 | KNOTT DAVID M JR | 73.0K -10.0K (-12.0%) | 6.38M +862.1K (+15.6%) | 0.11% -0.016 pp | 2.95% +0.729 pp | USD29.36 +197.5% | 10 qtrs — |
| 84 | WELLS FARGO & COMPANY/MN | 71.6K +23.9K (+49.9%) | 6.26M +3.1M (+97.1%) | 0.11% +0.037 pp | 0.00% +0.001 pp | USD52.81 +65.4% | 37 qtrs — |
| 85 | JANE STREET GROUP, LLC | 69.6K +43.8K (+169.8%) | 6.08M +4.4M (+254.7%) | 0.11% +0.069 pp | 0.00% +0.001 pp | USD74.32 +17.5% | 4 qtrs — |
| 86 | FISHER ASSET MANAGEMENT, LLC | 65.1K +65.1K (+100.0%) | 5.69M +5.7M (+100.0%) | 0.10% +0.102 pp | 0.00% +0.002 pp | USD87.34 +0.0% | 1 qtrs NEW |
| 87 | RAFFERTY ASSET MANAGEMENT, LLC | 63.7K -11.2K (-14.9%) | 5.56M +589.4K (+11.9%) | 0.10% -0.018 pp | 0.02% +0.003 pp | USD40.34 +116.5% | 22 qtrs — |
| 88 | STEMPOINT CAPITAL LP | 59.4K +11.5K (+23.9%) | 5.19M +2.0M (+62.9%) | 0.09% +0.018 pp | 0.89% +0.252 pp | USD62.61 +39.5% | 5 qtrs — |
| 89 | EAGLE HEALTH INVESTMENTS LP | 57.3K +57.3K (+100.0%) | 5.00M +5.0M (+100.0%) | 0.09% +0.090 pp | 1.10% +1.100 pp | USD87.34 +0.0% | 1 qtrs NEW |
| 90 | QUINN OPPORTUNITY PARTNERS LLC | 55.3K +55.3K (+100.0%) | 4.83M +4.8M (+100.0%) | 0.09% +0.087 pp | 0.20% +0.204 pp | USD87.34 +0.0% | 1 qtrs NEW |
| 91 | BIRCHVIEW CAPITAL, LP | 55.0K +7.0K (+14.6%) | 4.80M +1.6M (+50.7%) | 0.09% +0.011 pp | 2.81% +0.405 pp | USD29.02 +201.0% | 20 qtrs — |
| 92 | BESSEMER GROUP INC | 54.2K +49.9K (+1,166.9%) | 4.73M +4.4M (+1,571.7%) | 0.08% +0.078 pp | 0.01% +0.007 pp | USD85.54 +2.1% | 6 qtrs — |
| 93 | SILVERCREST ASSET MANAGEMENT GROUP LLC | 53.2K +— (+0.0%) | 4.65M +1.1M (+31.5%) | 0.08% 0.000 pp | 0.03% +0.009 pp | USD22.34 +291.0% | 19 qtrs — |
| 94 | EVERSEPT PARTNERS, LP | 53.0K +53.0K (+100.0%) | 4.63M +4.6M (+100.0%) | 0.08% +0.083 pp | 0.23% +0.233 pp | USD87.34 +0.0% | 11 qtrs — |
| 95 | PENTWATER CAPITAL MANAGEMENT LP | 50.0K +50.0K (+100.0%) | 4.37M +4.4M (+100.0%) | 0.08% +0.078 pp | 0.02% +0.023 pp | USD87.34 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
3.2K
Cash buys
—
Cash sales
1.00
Net activity
-3,210
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-23 | PATEL DINESH V PH D | Director / Officer | G-Gift | D | Common Stock | 1,460 | 0.00 | — | 523,478 | D | ↗ |
| 2026-04-20 | Ali Asif | Officer | S-Sale | D | Common Stock | 1,750 | 105.47 | 184.6K | 59,003 | D | ↗ |
| 2026-03-26 | SELICK HAROLD E | Director | M-Exempt | A | Common Stock | 24,000 | 12.88 | 309.1K | 84,845 | D | ↗ |
| 2026-03-26 | MOLINA ARTURO MD | Officer | M-Exempt | A | Common Stock | 15,000 | 8.04 | 120.6K | 99,115 | D | ↗ |
| 2026-03-26 | Ali Asif | Officer | M-Exempt | A | Common Stock | 5,265 | 12.17 | 64.1K | 85,518 | D | ↗ |
| 2026-03-25 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 54,641 | 101.00 | 5.52M | 524,938 | D | ↗ |
| 2026-03-24 | PATEL DINESH V PH D | Director / Officer | M-Exempt | A | Common Stock | 59 | 8.58 | 506.22 | 524,997 | D | ↗ |
| 2026-03-23 | PATEL DINESH V PH D | Director / Officer | G-Gift | D | Common Stock | 50,000 | 0.00 | — | 524,938 | D | ↗ |
| 2026-02-17 | Williams Lewis T | Director | M-Exempt | A | Common Stock | 18,000 | 10.84 | 195.1K | 25,825 | D | ↗ |
| 2026-02-06 | Waddill William D. | Director | M-Exempt | A | Common Stock | 20,000 | 8.31 | 166.2K | 27,825 | D | ↗ |
| 2026-01-27 | PATEL DINESH V PH D | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 4,068 | 21.58 | 87.8K | 300,000 | D | ↗ |
| 2026-01-27 | MOLINA ARTURO MD | Officer | M-Exempt | A | Common Stock | 5,000 | 8.04 | 40.2K | 89,115 | D | ↗ |
| 2026-01-27 | Ali Asif | Officer | S-Sale | D | Common Stock | 28,000 | 83.13 | 2.33M | 78,523 | D | ↗ |
| 2026-01-26 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 10,685 | 84.00 | 897.5K | 574,505 | D | ↗ |
| 2026-01-26 | MOLINA ARTURO MD | Officer | S-Sale | D | Common Stock | 5,000 | 82.28 | 411.4K | 84,115 | D | ↗ |
| 2026-01-23 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 19,315 | 84.59 | 1.63M | 574,505 | D | ↗ |
| 2026-01-23 | MOLINA ARTURO MD | Officer | S-Sale | D | Common Stock | 13,151 | 82.42 | 1.08M | 84,115 | D | ↗ |
| 2026-01-20 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 34,438 | 82.48 | 2.84M | 580,505 | D | ↗ |
| 2026-01-20 | MOLINA ARTURO MD | Officer | S-Sale | D | Common Stock | 9,514 | 82.48 | 784.7K | 97,266 | D | ↗ |
| 2026-01-20 | Ali Asif | Officer | S-Sale | D | Common Stock | 8,588 | 82.48 | 708.3K | 78,077 | D | ↗ |
| 2026-01-09 | SELICK HAROLD E | Director | M-Exempt | A | Common Stock | 14,299 | 4.21 | 60.2K | 60,845 | D | ↗ |
| 2026-01-02 | Williams Lewis T | Director | A-Award | A | Stock Option (right to buy) | 3,762 | 87.18 | 328.0K | 3,762 | D | ↗ |
| 2026-01-02 | Waddill William D. | Director | A-Award | A | Stock Option (right to buy) | 3,762 | 87.18 | 328.0K | 3,762 | D | ↗ |
| 2026-01-02 | SELICK HAROLD E | Director | A-Award | A | Stock Option (right to buy) | 3,762 | 87.18 | 328.0K | 3,762 | D | ↗ |
| 2026-01-02 | PATEL DINESH V PH D | Director / Officer | A-Award | A | Stock Option (right to buy) | 120,200 | 87.18 | 10.48M | 120,200 | D | ↗ |
| 2026-01-02 | O'Dowd Sarah A | Director | A-Award | A | Stock Option (right to buy) | 3,762 | 87.18 | 328.0K | 3,762 | D | ↗ |
| 2026-01-02 | MOLINA ARTURO MD | Officer | A-Award | A | Common Stock | 25,600 | 0.00 | — | 106,780 | D | ↗ |
| 2026-01-02 | Giraudo Bryan | Director | A-Award | A | Common Stock | 2,695 | 0.00 | — | 17,825 | D | ↗ |
| 2026-01-02 | Ali Asif | Officer | A-Award | A | Stock Option (right to buy) | 32,000 | 87.18 | 2.79M | 32,000 | D | ↗ |
| 2025-11-21 | PATEL DINESH V PH D | Director / Officer | G-Gift | D | Common Stock | 440 | 0.00 | — | 519,543 | D | ↗ |
| 2025-11-17 | MOLINA ARTURO MD | Officer | S-Sale | D | Common Stock | 2,712 | 84.77 | 229.9K | 81,180 | D | ↗ |
| 2025-10-10 | Waddill William D. | Director | M-Exempt | A | Common Stock | 12,000 | 6.98 | 83.8K | 17,130 | D | ↗ |
| 2025-09-22 | Waddill William D. | Director | S-Sale | D | Common Stock | 4,000 | 64.25 | 257.0K | 5,130 | D | ↗ |
| 2025-09-16 | PATEL DINESH V PH D | Director / Officer | G-Gift | D | Common Stock | 620 | 0.00 | — | 519,983 | D | ↗ |
| 2025-08-27 | Waddill William D. | Director | S-Sale | D | Common Stock | 4,000 | 59.25 | 237.0K | 9,130 | D | ↗ |
| 2025-07-25 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 10,415 | 54.78 | 570.5K | 520,603 | D | ↗ |
| 2025-07-23 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 17,520 | 54.79 | 959.9K | 531,018 | D | ↗ |
| 2025-07-22 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 22,065 | 55.05 | 1.21M | 548,538 | D | ↗ |
| 2025-07-21 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 12,859 | 54.86 | 705.4K | 570,603 | D | ↗ |
| 2025-07-16 | PATEL DINESH V PH D | Director / Officer | G-Gift | D | Common Stock | 5,000 | 0.00 | — | 558,462 | D | ↗ |
| 2025-06-16 | PATEL DINESH V PH D | Director / Officer | G-Gift | D | Common Stock | 685 | 0.00 | — | 562,905 | D | ↗ |
| 2025-06-13 | PATEL DINESH V PH D | Director / Officer | G-Gift | D | Common Stock | 670 | 0.00 | — | 563,590 | D | ↗ |
| 2025-06-10 | MOLINA ARTURO MD | Officer | M-Exempt | A | Common Stock | 10,000 | 8.04 | 80.4K | 93,892 | D | ↗ |
| 2025-06-09 | MOLINA ARTURO MD | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 8.04 | 80.4K | 85,971 | D | ↗ |
| 2025-04-28 | SELICK HAROLD E | Director | M-Exempt | D | Stock Option (right to buy) | 10,725 | 1.16 | 12.4K | 0 | D | ↗ |
| 2025-04-22 | Ali Asif | Officer | S-Sale | D | Common Stock | 1,756 | 46.00 | 80.8K | 61,065 | D | ↗ |
| 2025-03-17 | Waddill William D. | Director | S-Sale | D | Common Stock | 4,000 | 54.25 | 217.0K | 13,130 | D | ↗ |
| 2025-03-13 | MOLINA ARTURO MD | Officer | M-Exempt | A | Common Stock | 2,077 | 38.98 | 81.0K | 114,406 | D | ↗ |
| 2025-03-12 | Ali Asif | Officer | M-Exempt | D | Stock Option (right to buy) | 9,700 | 19.19 | 186.1K | 66,800 | D | ↗ |
| 2025-03-05 | PATEL DINESH V PH D | Director / Officer | M-Exempt | A | Common Stock | 24,000 | 4.21 | 101.0K | 564,260 | D | ↗ |
| 2025-02-19 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 5,359 | 38.18 | 204.6K | 540,260 | D | ↗ |
| 2025-01-16 | MOLINA ARTURO MD | Officer | S-Sale | D | Common Stock | 3,252 | 0.00 | — | 83,892 | D | ↗ |
| 2025-01-16 | Ali Asif | Officer | S-Sale | D | Common Stock | 2,601 | 0.00 | — | 62,821 | D | ↗ |
| 2025-01-15 | PATEL DINESH V PH D | Director / Officer | F-InKind | D | Common Stock | 12,636 | 0.00 | — | 545,619 | D | ↗ |
| 2025-01-02 | Williams Lewis T | Director | A-Award | A | Common Stock | 5,130 | 0.00 | — | 5,130 | D | ↗ |
| 2025-01-02 | Waddill William D. | Director | A-Award | A | Stock Option (right to buy) | 6,584 | 38.98 | 256.6K | 6,584 | D | ↗ |
| 2025-01-02 | SELICK HAROLD E | Director | A-Award | A | Stock Option (right to buy) | 6,584 | 38.98 | 256.6K | 6,584 | D | ↗ |
| 2025-01-02 | PATEL DINESH V PH D | Director / Officer | A-Award | A | Stock Option (right to buy) | 181,472 | 38.98 | 7.07M | 181,472 | D | ↗ |
| 2025-01-02 | O'Dowd Sarah A | Director | A-Award | A | Common Stock | 5,130 | 0.00 | — | 5,130 | D | ↗ |
| 2025-01-02 | MOLINA ARTURO MD | Officer | A-Award | A | Stock Option (right to buy) | 49,862 | 38.98 | 1.94M | 49,862 | D | ↗ |
| 2025-01-02 | Giraudo Bryan | Director | A-Award | A | Stock Option (right to buy) | 6,584 | 38.98 | 256.6K | 6,584 | D | ↗ |
| 2025-01-02 | Ali Asif | Officer | A-Award | A | Stock Option (right to buy) | 38,520 | 38.98 | 1.50M | 38,520 | D | ↗ |
| 2024-11-27 | MOLINA ARTURO MD | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 8.04 | 80.4K | 111,971 | D | ↗ |
| 2024-11-26 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 21,480 | 46.25 | 993.5K | 408,455 | D | ↗ |
| 2024-11-26 | MOLINA ARTURO MD | Officer | M-Exempt | D | Stock Option (right to buy) | 5,529 | 8.04 | 44.5K | 121,971 | D | ↗ |
| 2024-11-26 | Gupta Suneel | Officer | M-Exempt | D | Stock Option (right to buy) | 30,000 | 12.17 | 365.1K | 93,750 | D | ↗ |
| 2024-11-25 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 78,520 | 46.96 | 3.69M | 435,208 | D | ↗ |
| 2024-11-25 | Gupta Suneel | Officer | M-Exempt | A | Common Stock | 45,000 | 8.02 | 360.9K | 274,611 | D | ↗ |
| 2024-11-19 | PATEL DINESH V PH D | Director / Officer | G-Gift | D | Common Stock | 1,000 | 0.00 | — | 513,415 | D | ↗ |
| 2024-11-15 | MOLINA ARTURO MD | Officer | S-Sale | D | Common Stock | 1,906 | 40.98 | 78.1K | 46,444 | D | ↗ |
| 2024-09-11 | Ali Asif | Officer | M-Exempt | A | Common Stock | 6,000 | 19.19 | 115.1K | 40,960 | — | ↗ |
| 2024-09-10 | Waddill William D. | Director | M-Exempt | A | Common Stock | 8,000 | 12.88 | 103.0K | 20,000 | — | ↗ |
| 2024-07-24 | Waddill William D. | Director | M-Exempt | A | Common Stock | 8,000 | 12.88 | 103.0K | 20,000 | — | ↗ |
| 2024-06-13 | PATEL DINESH V PH D | Director / Officer | G-Gift | D | Common Stock | 1,000 | 0.00 | — | 514,415 | — | ↗ |
| 2024-06-07 | Waddill William D. | Director | M-Exempt | A | Common Stock | 8,000 | 12.88 | 103.0K | 20,000 | — | ↗ |
| 2024-06-07 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 35,000 | 35.19 | 1.23M | 515,415 | — | ↗ |
| 2024-04-18 | Ali Asif | Officer | S-Sale | D | Common Stock | 1,234 | 25.11 | 31.0K | 37,163 | — | ↗ |
| 2024-04-01 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 25,000 | 28.31 | 707.8K | 549,590 | — | ↗ |
| 2024-03-07 | SELICK HAROLD E | Director | M-Exempt | A | Common Stock | 6,490 | 1.89 | 12.3K | 27,996 | — | ↗ |
| 2024-03-01 | Waddill William D. | Director | M-Exempt | A | Common Stock | 12,975 | 6.09 | 79.0K | 24,975 | — | ↗ |
| 2024-03-01 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 30,000 | 31.62 | 948.6K | 574,590 | — | ↗ |
| 2024-03-01 | Ali Asif | Officer | S-Sale | D | Common Stock | 12,000 | 32.22 | 386.6K | 40,645 | — | ↗ |
| 2024-02-29 | Ali Asif | Officer | S-Sale | D | Common Stock | 7,850 | 30.61 | 240.3K | 42,734 | — | ↗ |
| 2024-02-26 | PATEL DINESH V PH D | Director / Officer | F-InKind | D | Common Stock | 10,915 | 29.53 | 322.3K | 604,590 | — | ↗ |
| 2024-02-26 | Gupta Suneel | Officer | F-InKind | D | Common Stock | 4,282 | 29.53 | 126.4K | 183,285 | — | ↗ |
| 2024-02-15 | PATEL DINESH V PH D | Director / Officer | F-InKind | D | Common Stock | 3,717 | 28.23 | 104.9K | 615,505 | — | ↗ |
| 2024-01-16 | MOLINA ARTURO MD | Officer | F-InKind | D | Common Stock | 427 | 24.63 | 10.5K | 48,350 | — | ↗ |
| 2024-01-16 | Ali Asif | Officer | F-InKind | D | Common Stock | 1,452 | 24.63 | 35.8K | 50,584 | — | ↗ |
| 2024-01-09 | Gupta Suneel | Officer | S-Sale | D | Common Stock | 5,000 | 25.00 | 125.0K | 187,567 | — | ↗ |
| 2024-01-02 | Williams Lewis T | Director | A-Award | A | Stock Option (right to buy) | 25,700 | 23.42 | 601.9K | 25,700 | — | ↗ |
| 2024-01-02 | Waddill William D. | Director | A-Award | A | Stock Option (right to buy) | 25,700 | 23.42 | 601.9K | 25,700 | — | ↗ |
| 2024-01-02 | SELICK HAROLD E | Director | A-Award | A | Stock Option (right to buy) | 25,700 | 23.42 | 601.9K | 25,700 | — | ↗ |
| 2024-01-02 | PATEL DINESH V PH D | Director / Officer | A-Award | A | Common Stock | 84,875 | 0.00 | — | 619,222 | — | ↗ |
| 2024-01-02 | O'Dowd Sarah A | Director | A-Award | A | Stock Option (right to buy) | 25,700 | 23.42 | 601.9K | 25,700 | — | ↗ |
| 2024-01-02 | MOLINA ARTURO MD | Officer | A-Award | A | Stock Option (right to buy) | 97,500 | 23.42 | 2.28M | 97,500 | — | ↗ |
| 2024-01-02 | Gupta Suneel | Officer | A-Award | A | Common Stock | 19,250 | 0.00 | — | 187,567 | — | ↗ |
| 2024-01-02 | Giraudo Bryan | Director | A-Award | A | Stock Option (right to buy) | 25,700 | 23.42 | 601.9K | 25,700 | — | ↗ |
| 2024-01-02 | Ali Asif | Officer | A-Award | A | Stock Option (right to buy) | 78,000 | 23.42 | 1.83M | 78,000 | — | ↗ |
| 2023-12-13 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 75,000 | 20.08 | 1.51M | 534,347 | — | ↗ |
| 2023-11-15 | MOLINA ARTURO MD | Officer | S-Sale | D | Common Stock | 1,848 | 16.24 | 30.0K | 22,527 | — | ↗ |
| 2023-10-26 | Swisher Daniel N JR | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-10-19 | Gupta Suneel | Officer | M-Exempt | D | Stock Option (right to buy) | 20,000 | 7.38 | 147.6K | 50,000 | — | ↗ |
| 2023-10-18 | PATEL DINESH V PH D | Director / Officer | M-Exempt | A | Common Stock | 6,000 | 4.21 | 25.3K | 609,347 | — | ↗ |
| 2023-05-31 | PATEL DINESH V PH D | Director / Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 615,111 | — | ↗ |
| 2023-05-31 | Gupta Suneel | Officer | A-Award | A | Common Stock | 12,000 | 0.00 | — | 152,187 | — | ↗ |
| 2023-05-31 | Ali Asif | Officer | A-Award | A | Common Stock | 12,000 | 0.00 | — | 35,186 | — | ↗ |
| 2023-04-18 | Ali Asif | Officer | F-InKind | D | Common Stock | 1,189 | 23.21 | 27.6K | 23,186 | — | ↗ |
| 2023-04-10 | SELICK HAROLD E | Director | M-Exempt | A | Common Stock | 6,196 | 0.87 | 5.4K | 21,506 | — | ↗ |
| 2023-02-22 | PATEL DINESH V PH D | Director / Officer | G-Gift | D | Common Stock | 10,000 | 0.00 | — | 583,448 | — | ↗ |
| 2023-01-16 | Williams Lewis T | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2023-01-16 | Waddill William D. | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2023-01-16 | SELICK HAROLD E | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2023-01-16 | PATEL DINESH V PH D | Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 0.00 | — | 600,000 | — | ↗ |
| 2023-01-16 | O'Dowd Sarah A | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2023-01-16 | Noonberg Sarah B. | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2023-01-16 | MOLINA ARTURO MD | Officer | A-Award | A | Stock Option (right to buy) | 18,750 | 0.00 | — | 18,750 | — | ↗ |
| 2023-01-16 | Gupta Suneel | Officer | A-Award | A | Common Stock | 20,625 | 0.00 | — | 138,187 | — | ↗ |
| 2023-01-16 | Giraudo Bryan | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2023-01-16 | Ali Asif | Officer | A-Award | A | Common Stock | 10,625 | 0.00 | — | 24,375 | — | ↗ |
| 2022-12-28 | PATEL DINESH V PH D | Officer | G-Gift | D | Common Stock | 3,116 | 0.00 | — | 598,096 | — | ↗ |
| 2022-11-16 | Liu David Y | Officer | M-Exempt | D | Stock Option (right to buy) | 35,331 | 0.00 | — | 0 | — | ↗ |
| 2022-11-15 | MOLINA ARTURO MD | Officer | A-Award | A | Stock Option (right to buy) | 127,500 | 0.00 | — | 127,500 | — | ↗ |
| 2022-11-07 | MOLINA ARTURO MD | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-23 | PATEL DINESH V PH D | Officer | M-Exempt | A | Common Stock | 20,000 | 4.21 | 84.2K | 604,048 | — | ↗ |
| 2022-05-26 | Williams Lewis T | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-26 | Waddill William D. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-26 | SELICK HAROLD E | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 8.31 | 166.2K | 20,000 | — | ↗ |
| 2022-05-26 | O'Dowd Sarah A | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-26 | Noonberg Sarah B. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-26 | Giraudo Bryan | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 8.31 | 166.2K | 20,000 | — | ↗ |
| 2022-05-04 | PATEL DINESH V PH D | Officer | G-Gift | D | Common Stock | 3,000 | 0.00 | — | 581,048 | — | ↗ |
| 2022-05-03 | Waddill William D. | Director | M-Exempt | A | Common Stock | 12,000 | 8.59 | 103.1K | 12,000 | — | ↗ |
| 2022-04-26 | PATEL DINESH V PH D | Officer | M-Exempt | A | Common Stock | 30,000 | 4.21 | 126.3K | 568,306 | — | ↗ |
| 2022-04-26 | Gupta Suneel | Officer | M-Exempt | D | Stock Option (right to buy) | 40,000 | 0.00 | — | 70,000 | — | ↗ |
| 2022-04-18 | Ali Asif | Officer | A-Award | A | Common Stock | 13,750 | 0.00 | — | 13,750 | — | ↗ |
| 2022-04-14 | PATEL DINESH V PH D | Officer | M-Exempt | D | Stock Option (right to buy) | 34,087 | 0.00 | — | 0 | — | ↗ |
| 2022-02-28 | PATEL DINESH V PH D | Director / Officer | F-InKind | D | Common Stock | 4,648 | 24.28 | 112.9K | 503,760 | — | ↗ |
| 2022-02-28 | Liu David Y | Officer | F-InKind | D | Common Stock | 2,119 | 24.28 | 51.4K | 66,538 | — | ↗ |
| 2022-02-28 | Gupta Suneel | Officer | F-InKind | D | Common Stock | 649 | 24.28 | 15.8K | 77,007 | — | ↗ |
| 2022-02-15 | PATEL DINESH V PH D | Director / Officer | A-Award | A | Common Stock | 31,250 | 0.00 | — | 508,408 | — | ↗ |
| 2022-02-15 | Liu David Y | Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 68,657 | — | ↗ |
| 2022-02-15 | Kalkofen Donald A. | Officer | A-Award | A | Common Stock | 7,500 | 0.00 | — | 18,521 | — | ↗ |
| 2022-02-15 | Gupta Suneel | Officer | A-Award | A | Common Stock | 12,500 | 0.00 | — | 77,656 | — | ↗ |
| 2021-12-21 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 15,000 | 32.14 | 482.2K | 477,158 | — | ↗ |
| 2021-09-21 | PATEL DINESH V PH D | Director / Officer | M-Exempt | A | Common Stock | 40,000 | 4.21 | 168.4K | 492,158 | — | ↗ |
| 2021-08-17 | Liu David Y | Officer | M-Exempt | A | Common Stock | 10,000 | 0.87 | 8.7K | 73,033 | — | ↗ |
| 2021-05-27 | Williams Lewis T | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 35.23 | 634.1K | 18,000 | — | ↗ |
| 2021-05-27 | Waddill William D. | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 35.23 | 634.1K | 18,000 | — | ↗ |
| 2021-05-27 | SELICK HAROLD E | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 35.23 | 634.1K | 18,000 | — | ↗ |
| 2021-05-27 | O'Dowd Sarah A | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 35.23 | 634.1K | 18,000 | — | ↗ |
| 2021-05-27 | Noonberg Sarah B. | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 35.23 | 634.1K | 18,000 | — | ↗ |
| 2021-05-27 | Giraudo Bryan | Director | A-Award | A | Stock Option (right to buy) | 18,000 | 35.23 | 634.1K | 18,000 | — | ↗ |
| 2021-02-26 | Saks Samuel R | Officer | A-Award | A | Common Stock | 12,000 | 0.00 | — | 14,000 | — | ↗ |
| 2021-02-26 | PATEL DINESH V PH D | Director / Officer | A-Award | A | Stock Option (right to buy) | 225,000 | 23.57 | 5.30M | 225,000 | — | ↗ |
| 2021-02-26 | Liu David Y | Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 62,427 | — | ↗ |
| 2021-02-26 | Kalkofen Donald A. | Officer | A-Award | A | Common Stock | 7,500 | 0.00 | — | 10,386 | — | ↗ |
| 2021-02-26 | Gupta Suneel | Officer | A-Award | A | Common Stock | 12,000 | 0.00 | — | 63,987 | — | ↗ |
| 2021-02-11 | Noonberg Sarah B. | Director | A-Award | A | Common Stock | 3,700 | 6.98 | 25.8K | 3,700 | — | ↗ |
| 2021-02-10 | Noonberg Sarah B. | Director | M-Exempt | D | Stock Option (right to buy) | 4,700 | 6.98 | 32.8K | 7,300 | — | ↗ |
| 2021-01-19 | PATEL DINESH V PH D | Director / Officer | M-Exempt | A | Common Stock | 13,000 | 4.21 | 54.7K | 450,990 | — | ↗ |
| 2020-08-17 | O'Dowd Sarah A | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 16.50 | 495.0K | 30,000 | — | ↗ |
| 2020-08-12 | O'Dowd Sarah A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-08-11 | KHOSLA CHAITAN PHD | Director | M-Exempt | D | Stock Option (right to buy) | 2,499 | 1.89 | 4.7K | 7,499 | — | ↗ |
| 2020-05-28 | Williams Lewis T | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 16.54 | 248.1K | 15,000 | — | ↗ |
| 2020-05-28 | Waddill William D. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 16.54 | 248.1K | 15,000 | — | ↗ |
| 2020-05-28 | SELICK HAROLD E | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 16.54 | 248.1K | 15,000 | — | ↗ |
| 2020-05-28 | Noonberg Sarah B. | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 16.54 | 248.1K | 15,000 | — | ↗ |
| 2020-05-28 | KHOSLA CHAITAN PHD | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 16.54 | 248.1K | 15,000 | — | ↗ |
| 2020-05-28 | Giraudo Bryan | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 16.54 | 248.1K | 15,000 | — | ↗ |
| 2020-04-29 | PATEL DINESH V PH D | Director / Officer | G-Gift | D | Common Stock | 2,000 | 0.00 | — | 437,990 | — | ↗ |
| 2020-03-20 | PATEL DINESH V PH D | Director / Officer | M-Exempt | A | Common Stock | 10,000 | 1.89 | 18.9K | 439,990 | — | ↗ |
| 2020-03-12 | SELICK HAROLD E | Director | P-Purchase | A | Common Stock | 12,000 | 6.70 | 80.4K | 15,310 | — | ↗ |
| 2020-03-12 | PATEL DINESH V PH D | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 18,344 | 1.16 | 21.3K | 0 | — | ↗ |
| 2020-02-28 | Saks Samuel R | Officer | A-Award | A | Stock Option (right to buy) | 85,000 | 7.80 | 663.0K | 85,000 | — | ↗ |
| 2020-02-28 | PATEL DINESH V PH D | Director / Officer | A-Award | A | Stock Option (right to buy) | 235,000 | 7.80 | 1.83M | 235,000 | — | ↗ |
| 2020-02-28 | Liu David Y | Officer | A-Award | A | Stock Option (right to buy) | 70,000 | 7.80 | 546.0K | 70,000 | — | ↗ |
| 2020-02-28 | Kalkofen Donald A. | Officer | A-Award | A | Stock Option (right to buy) | 55,000 | 7.80 | 429.0K | 55,000 | — | ↗ |
| 2020-02-28 | Gupta Suneel | Officer | A-Award | A | Stock Option (right to buy) | 85,000 | 7.80 | 663.0K | 85,000 | — | ↗ |
| 2019-12-03 | PATEL DINESH V PH D | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 5.65 | 113.0K | 409,824 | — | ↗ |
| 2019-12-03 | Kalkofen Donald A. | Officer | P-Purchase | A | Common Stock | 562 | 5.09 | 2.9K | 1,175 | — | ↗ |
| 2019-12-03 | Gupta Suneel | Officer | P-Purchase | A | Common Stock | 30,000 | 5.13 | 153.9K | 49,500 | — | ↗ |
| 2019-12-03 | Giraudo Bryan | Director | P-Purchase | A | Common Stock | 8,000 | 5.70 | 45.6K | 8,000 | — | ↗ |
| 2019-11-26 | PATEL DINESH V PH D | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 4,000 | 1.16 | 4.6K | 18,343 | — | ↗ |
| 2019-08-15 | KHOSLA CHAITAN PHD | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 9.99 | 50.0K | 5,000 | — | ↗ |
| 2019-08-06 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 10,792 | 8.85 | 95.5K | 374,792 | — | ↗ |
| 2019-08-06 | Liu David Y | Officer | S-Sale | D | Common Stock | 3,395 | 8.85 | 30.0K | 49,802 | — | ↗ |
| 2019-06-07 | Williams Lewis T | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 11.80 | 141.6K | 12,000 | — | ↗ |
| 2019-06-07 | Waddill William D. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 11.80 | 141.6K | 12,000 | — | ↗ |
| 2019-06-07 | SELICK HAROLD E | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 11.80 | 141.6K | 12,000 | — | ↗ |
| 2019-06-07 | Noonberg Sarah B. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 11.80 | 141.6K | 12,000 | — | ↗ |
| 2019-06-07 | KHOSLA CHAITAN PHD | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 11.80 | 141.6K | 12,000 | — | ↗ |
| 2019-06-07 | Giraudo Bryan | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 11.80 | 141.6K | 12,000 | — | ↗ |
| 2019-05-31 | Kalkofen Donald A. | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 10.06 | 1.01M | 100,000 | — | ↗ |
| 2019-05-28 | Kalkofen Donald A. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-05-15 | Saks Samuel R | Officer | A-Award | A | Stock Option (right to buy) | 45,000 | 10.80 | 486.0K | 45,000 | — | ↗ |
| 2019-04-01 | SELICK HAROLD E | Director | M-Exempt | A | Common Stock | 3,310 | 1.31 | 4.3K | 3,310 | — | ↗ |
| 2019-03-01 | Shames Richard S. | Officer | S-Sale | D | Common Stock | 657 | 8.03 | 5.3K | 32,021 | — | ↗ |
| 2019-03-01 | PATEL DINESH V PH D | Director / Officer | S-Sale | D | Common Stock | 2,183 | 8.03 | 17.5K | 383,831 | — | ↗ |
| 2019-03-01 | Liu David Y | Officer | S-Sale | D | Common Stock | 810 | 8.03 | 6.5K | 51,197 | — | ↗ |
| 2019-02-28 | Shames Richard S. | Officer | A-Award | A | Common Stock | 8,500 | 0.00 | — | 32,678 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-10.4K
Shares Outstanding
63.81M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Dinesh V. Patel, Ph.D. President and Chief Executive Officer | 715.5K | — | 5.84M | 5.62M | 686.9K | 11.9K | 12.87M | 89.01% | ↗ |
| 2 | 2025 | Arturo Molina, M.D., M.S., F.A.C.P. Chief Medical Officer | 572.0K | — | 1.60M | 1.54M | 366.1K | 11.9K | 4.10M | 76.80% | ↗ |
| 3 | 2025 | Asif Ali EVP, Chief Financial Officer | 500.0K | — | 1.24M | 1.19M | 320.0K | 6.2K | 3.26M | 74.64% | ↗ |
| 4 | 2024 | Dinesh V. Patel, Ph.D. President and Chief Executive Officer | 681.4K | 112.4K | 1.99M | 6.12M | 562.2K | 10.9K | 9.47M | 85.57% | ↗ |
| 5 | 2024 | Arturo Molina, M.D., M.S., F.A.C.P. Chief Medical Officer | 550.0K | 66.0K | 614.8K | 1.89M | 330.0K | 10.9K | 3.46M | 72.38% | ↗ |
| 6 | 2024 | Asif Ali EVP, Chief Financial Officer | 465.0K | 55.8K | 491.8K | 1.51M | 279.0K | 5.2K | 2.81M | 71.36% | ↗ |
| 7 | 2024 | Suneel Gupta, Ph.D. Chief Development Officer | 530.5K | 63.7K | 450.8K | 1.39M | 291.8K | 10.9K | 2.74M | 67.21% | ↗ |
| 8 | 2023 | Dinesh V. Patel, Ph.D. President and Chief Executive Officer | 655.2K | — | — | 6.04M | 360.4K | 10.9K | 7.07M | 85.48% | ↗ |
| 9 | 2023 | Suneel Gupta, Ph.D. Chief Development Officer | 515.2K | — | 251.0K | 1.25M | 193.1K | 10.9K | 2.22M | 67.55% | ↗ |
| 10 | 2023 | Asif Ali EVP, Chief Financial Officer | 447.0K | — | 129.3K | 641.9K | 178.8K | 5.2K | 1.40M | 55.00% | ↗ |
| 11 | 2022 | Dinesh V. Patel, Ph.D. President and Chief Executive Officer | 630.0K | — | 897.8K | 4.21M | 242.6K | 10.9K | 5.99M | 85.26% | ↗ |
| 12 | 2022 | Suneel Gupta, Ph.D. Chief Development Officer | 500.0K | — | 359.1K | 1.68M | 130.0K | 10.9K | 2.68M | 76.13% | ↗ |
| 13 | 2022 | David Y. Liu, Ph.D. Former Chief Research and Development Strategy Officer | 475.0K | — | 287.3K | 1.35M | 123.5K | 15.2K | 2.25M | 72.71% | ↗ |
| 14 | 2021 | Dinesh V. Patel, Ph.D. President and Chief Executive Officer | 600.0K | — | 589.3K | 3.92M | 429.0K | 7.1K | 5.54M | 81.31% | ↗ |
| 15 | 2021 | Suneel Gupta, Ph.D Chief Development Officer | 455.0K | — | 282.8K | 1.39M | 236.6K | 7.1K | 2.38M | 70.58% | ↗ |
| 16 | 2021 | Suneel Gupta, Ph.D. Chief Development Officer | 455.0K | — | 282.8K | 1.39M | 236.6K | 7.1K | 2.38M | 70.58% | ↗ |
| 17 | 2021 | David Y. Liu, Ph.D. Former Chief Research and Development Strategy Officer | 455.0K | — | 235.7K | 1.13M | 233.2K | 14.7K | 2.07M | 66.06% | ↗ |
| 18 | 2021 | David Y. Liu, Ph.D. Chief Research and Development Strategy Officer | 455.0K | — | 235.7K | 1.13M | 233.2K | 14.7K | 2.07M | 66.06% | ↗ |
| 19 | 2020 | Dinesh V. Patel, Ph.D. President and Chief Executive Officer | 565.0K | — | — | 1.18M | 473.9K | 3.6K | 2.23M | 53.16% | ↗ |
| 20 | 2020 | Suneel Gupta, Ph.D Chief Development Officer | 420.0K | — | — | 428.0K | 256.2K | 4.1K | 1.11M | 38.61% | ↗ |
| 21 | 2020 | Suneel Gupta, Ph.D. Chief Development Officer | 420.0K | — | — | 428.0K | 256.2K | 4.1K | 1.11M | 38.61% | ↗ |
| 22 | 2020 | David Y. Liu, Ph.D. Chief Scientific Officer and Head of Discovery and Pre-Clinical Development | 441.3K | — | — | 352.4K | 267.0K | 11.1K | 1.07M | 32.88% | ↗ |
| 23 | 2020 | David Y. Liu, Ph.D. Chief Research and Development Strategy Officer | 441.3K | — | — | 352.4K | 267.0K | 11.1K | 1.07M | 32.88% | ↗ |
| 24 | 2019 | Dinesh V. Patel, Ph.D. President and Chief Executive Officer | 545.0K | — | 230.6K | 814.4K | 354.3K | 4.2K | 1.95M | 53.63% | ↗ |
| 25 | 2019 | Suneel Gupta, Ph.D. Chief Development Officer | 377.5K | — | 60.2K | 693.8K | 196.8K | 3.6K | 1.33M | 56.61% | ↗ |
| 26 | 2019 | David Y. Liu, Ph.D. Chief Scientific Officer and Head of Discovery and Pre-Clinical Development | 428.5K | — | 120.3K | 424.9K | 218.5K | 7.5K | 1.20M | 45.45% | ↗ |
| 27 | 2019 | David Y. Liu, Ph.D. Chief Scientific Officer and Head of Research and Development | 428.5K | — | 120.3K | 424.9K | 218.5K | 7.5K | 1.20M | 45.45% | ↗ |
| 28 | 2018 | Dinesh V. Patel, Ph.D. President and Chief Executive Officer | 520.0K | — | 1.13M | 1.84M | 221.0K | 10.8K | 3.72M | 79.80% | ↗ |
| 29 | 2018 | David Y. Liu, Ph.D. Chief Scientific Officer and Head of Research & Development | 410.0K | — | 382.4K | 677.0K | 141.5K | 7.5K | 1.62M | 65.46% | ↗ |
| 30 | 2018 | David Y. Liu, Ph.D. Chief Scientific Officer and Head of Research and Development | 410.0K | — | 382.4K | 677.0K | 141.5K | 7.5K | 1.62M | 65.46% | ↗ |
| 31 | 2018 | Richard S. Shames, M.D. Chief Medical Officer | 400.0K | — | 271.1K | 454.7K | 130.0K | 2.3K | 1.26M | 57.69% | ↗ |
| 32 | 2018 | Suneel Gupta, Ph.D. Chief Development Officer | — | — | — | — | — | 98.1K | 98.1K | 0.00% | ↗ |
| 33 | 2017 | Dinesh V. Patel, Ph.D. President and Chief Executive Officer | 475.0K | — | — | — | 309.0K | 6.1K | 790.1K | 0.00% | ↗ |
| 34 | 2017 | David Y. Liu, Ph.D. Chief Scientific Officer and Head of Research & Development | 357.0K | — | — | — | 186.0K | 9.2K | 552.2K | 0.00% | ↗ |
| 35 | 2017 | Richard S. Shames, M.D. Chief Medical Officer | 357.0K | — | — | — | 179.0K | 3.3K | 539.3K | 0.00% | ↗ |
| 36 | 2016 | Dinesh V. Patel, Ph.D. President and Chief Executive Officer | 400.0K | — | — | 4.43M | 160.0K | — | 4.99M | 88.78% | ↗ |
| 37 | 2016 | Richard Shames, M.D. Chief Medical Officer | 326.0K | — | — | 909.5K | 96.6K | 420.00 | 1.33M | 68.26% | ↗ |
| 38 | 2016 | Richard S. Shames, M.D. Chief Medical Officer | 326.0K | — | — | 909.5K | 96.6K | 420.00 | 1.33M | 68.26% | ↗ |
| 39 | 2016 | David Y. Liu, Ph.D. Chief Scientific Officer and Head of Research & Development | 310.0K | — | — | 922.7K | 93.0K | — | 1.33M | 69.60% | ↗ |
| 40 | 2015 | Dinesh V. Patel, Ph.D. President and Chief Executive Officer | 386.3K | — | — | 87.7K | 128.4K | — | 602.4K | 14.56% | ↗ |
| 41 | 2015 | David Y. Liu, Ph.D. Chief Scientific Officer and Head of Research & Development | 275.9K | — | — | 29.6K | 65.5K | — | 371.0K | 7.98% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dinesh V. Patel | Chief Executive Officer, President, Secretary & Director | 1M | — |
| Arturo Molina FACP | Chief Medical Officer | 950.0K | — |
| Asif Ali | Executive Vice President & Chief Financial Officer | 826.2K | male |
| Carter J. King | Executive Vice President of Business Development | — | male |
| Matthew Gosling | Executive Vice President and Chief Legal & Business Officer | — | male |
| Mohammad Masjedizadeh | Executive Vice President & Chief Technology Officer | — | male |
| Newman Yeilding | Executive Vice President, Chief Scientific Officer | — | — |
| Samuel R. Saks | Clinical Development Advisor | — | — |
| Abha Bommireddi | Executive Vice President & Chief of Staff | — | female |
| Venkat Thalladi | EVP & Chief Technical Officer | — | male |
| Ashok Bhandari | EVP & Chief Discovery Officer | — | — |
| Carena Spivey | Executive VP & Chief Human Resources Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PTGX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
